Skin. There’s nothing
quite like it.
Skin. The body’s largest organ, and undoubtedly its most mysterious. Perfect skin is the embodiment of beauty, a sign of health and wellbeing. It is said that perfect skin comes from the inside. The imperfect skin however can cause great discomfort to those afflicted by it, both physically and emotionally. For us, there is no greater challenge than to explore skin and get to the bottom of things. To give people the best skin imaginable.
The Mii DNA
With this mission in mind – creating better dermatology, quickly and effectively – we designed the Fund+Lab model. Vertically integrated, from invention to market, we understand the journey to success starts with a spark of innovation and smart R&D, continues with the deep understanding of clinical needs and market dynamics, and is ultimately fueled by exceptional human capital.
Our network of trust with entrepreneurs and academia, startups and investors, big pharma and key opinion leaders provides unique insights and unparalleled access. We not only look for opportunities, we create them.
As Maruho’s Head of Global Strategy, Junichi has led the company’s global business strategy ever since 2009.
He has played a key role in the company’s entrance into the Israeli innovation ecosystem. He is a member of Mii’s Investing Committee.
Junichi has served on the Board of Directors for Maruho’s subsidiaries in Europe and the US, and has served as Managing Director of Maruho Deutschland GmbH. He has overseen the restructuring of Maruho’s global business, including the sale of Maruho subsidiary Cutanea Life Sciences, Inc., to Biofrontera AG. Mr. Hamada was previously in charge of the Corporate Planning Department at Maruho, and prior to that was the CEO of Yatsude Co., Ltd., a pharmacy chain which was bought out by Maruho.
Junichi holds an MBA from the Arthur D. Little School of Management in Boston, Massachusetts, and B.A. in Pharmacy from Nihon University.
For the past 15 years Eran has been intricately involved in healthcare innovation, both as an entrepreneur and as a venture capital investor.
Eran is deeply rooted in the Israeli life-science ecosystem as a co-founder and board member of several pharmaceutical companies including ICD Pharma, Musli Thyropeutics, Seanergy Dermatology, Follicle Pharma, and others. He serves as the Chairman of the Investment Committee.
Formerly, Eran served as a Managing Director and Partner of Israel Healthcare Ventures (IHCV), a healthcare focused venture capital group, as a consultant in McKinsey & Company, serving clients worldwide in the Pharmaceutical, Telecom, and Government sectors, and as a member of the Global Marketing group at Novartis Oncology in New Jersey, USA.
Before moving to private sector, Eran served in the Israeli Ministry of Justice, as a Senior Advisor to the Director General of the Ministry.
Eran holds an MBA from Columbia University, an LL.B. in Law from Tel Aviv University, and a B.Sc. in Mathematics and Computer Science from Tel Aviv University.
Dr. Doron Friedman,
With more than 80 patents, many of them in the field of drug delivery systems, Doron is one of the most active pharma inventors around. His innovations are behind drugs selling under some of the world’s leading brands — products such as Lotemax™, Scytera™, Finacea™ and others. In MII Doron is an investor and inventor. He is one of the founders of MII, and the inventor behind a couple of its portfolio companies.
With a PhD in pharmaceutical sciences from the School of Pharmacy at the Hebrew University in Jerusalem, Doron has published over twenty peer-reviewed papers and over seventy patents in the field of drug delivery systems. Doron is the proud inventor of Lotemax™, Scytera™ and Finacea™ among others. He has also served as CTO at Pharmos Corp., and was a co-founder of Foamix Ltd (NASDAQ FOAMX), and ICDPharma Ltd.
Dr. Friedman is a co-founder of Foamix (NASDAQ FOAMX), ICD Pharma, Seanergy Dermatology and Foillcle Pharma. Formerly he has served as VP R&D of Lipocure and has led R&D in several other companies. Doron was a research associate at the liposomes and membrane laboratory at the Hebrew University of Jerusalem and a lecturer at the School of Engineering at the Hebrew University of Jerusalem. He held a post doctoral position at the School of Pharmacy Ann-Arbor, Michigan in Prof Gordon Amidon’s laboratories.
Doron holds a Ph.D. in Pharmaceutical Sciences from the Hebrew University Jerusalem.
Masa’s passion is the innovation-driven evolution of Japan’s economy. He has led a series of initiatives aimed to create a strategic bridge between Israel and Japan, one of them is the creation of MII Fund & Labs.
Masa, a Harvard-educated, McKinsey-experienced strategic consultant, has been supporting as many as 200 corporations both Japanese and global, in a variety of aspects – marketing, strategy, R&D, new business development, turn-around, alliances, M&A, and strategic resource allocation of conglomerates. He has served clients across all sectors including healthcare, manufacturing, services, logistics and more.
Masa is an expert in the evolution of strategic thinking of both individuals and organizations and has authored several books this issue.
Formerly, Masa has served on the legal and policy making staff in the Government of Japan, Ministry of Agriculture, Forestry and Fisheries. He is a Board member of Business Model Academy and a Director of the Japan Israel Chamber of Commerce.
Masa holds an MBA from Harvard University, and BA in international economics, law, and relations from the University of Tokyo.